title: Preferences and Stated Adherence for Antibiotic Treatment of Cystic Fibrosis Pseudomonas Infections.
abstract: OBJECTIVE
  Our objective was to quantify preferences and stated adherence for inhaled antibiotic treatments in cystic fibrosis (CF).
  
  
  METHODS
  Adult CF patients and parents of pediatric patients in the US who were members of the Cystic Fibrosis Foundation and who had Pseudomonas aeruginosa at least twice a year completed an online, discrete-choice experiment survey (response rate 4.4 %). Respondents answered five treatment-choice questions evaluating pairs of hypothetical CF treatment profiles. Stated-adherence questions followed two randomly selected treatment-choice questions. Data were analyzed using random-parameters logit (RPL). For a combination of attribute levels, the utility is estimated by summing the relevant attribute-level parameter estimates. For the stated-adherence questions, we tabulated the changes in the percentages of respondents who would be 95 % adherent for various changes in inhaled antibiotic-medication administration features.
  
  
  RESULTS
  The final sample was 271 adult patients and 209 parents. Switching from a 30-min nebulizer twice daily to a 10-min dry powder inhaler (DPI) twice daily was 6.3 times more important for patients and 2.0 times more important for parents than an improvement in dry cough side effect from moderate to mild. Stated adherence for respondents was 20-30 % greater for DPIs versus nebulizers.
  
  
  CONCLUSIONS
  Lower frequency of administration, shorter administration times for a given device, and milder dry cough appear to improve stated adherence to antibiotic treatment of CF lung infections.
authors.affiliation: RTI-Health Solutions, Research Triangle Park, NC, USA.
authors.forename: Ateesha Farah
authors.initials: AF
authors.lastname: Mohamed
authors.affiliation: RTI-Health Solutions, Research Triangle Park, NC, USA. reed.johnson@duke.edu.|Center for Clinical and Genetic Economics, Duke Clinical Research Institute, Duke University, 2400 Pratt Street, Durham, NC, 27705, USA. reed.johnson@duke.edu.
authors.forename: F Reed
authors.initials: FR
authors.lastname: Johnson
authors.affiliation: Novartis Pharma AG, Basel, Switzerland.
authors.forename: Maria-Magdalena
authors.initials: MM
authors.lastname: Balp
authors.affiliation: Novartis Pharma AG, Basel, Switzerland.
authors.forename: Frederico
authors.initials: F
authors.lastname: Calado
mesh_terms: D000280:Administration, Inhalation; D000293:Adolescent; D000328:Adult; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002648:Child; D003550:Cystic Fibrosis / Q000150:complications*; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008297:Male; D055118:Medication Adherence; D008875:Middle Aged; D009330:Nebulizers and Vaporizers; D010290:Parents; D057240:Patient Preference; D011552:Pseudomonas Infections / Q000188:drug therapy* / Q000209:etiology*; D013997:Time Factors
chemical_list: D000900:Anti-Bacterial Agents
references.citation: Patient Educ Couns. 2009 Apr;75(1):141-4
references.pmid: 18952395
references.citation: Patient. 2010 Dec 1;3(4):249-56
references.pmid: 22273432
references.citation: Health Econ. 2005 Oct;14(10):1079-83
references.pmid: 15852455
references.citation: J Pediatr. 1990 May;116(5):714-9
references.pmid: 2109790
references.citation: Value Health. 2011 Jun;14(4):403-13
references.pmid: 21669364
references.citation: J Cyst Fibros. 2011 Jul;10(4):258-64
references.pmid: 21458391
references.citation: Pediatr Pulmonol. 2009 Oct;44(10):989-96
references.pmid: 19768806
references.citation: Am J Clin Pathol. 2007 Jul;128(1):32-4
references.pmid: 17580270
references.citation: Pediatr Pulmonol. 2011 Mar;46(3):230-8
references.pmid: 20963831
references.citation: Support Care Cancer. 2015 Jan;23 (1):21-8
references.pmid: 24939674
references.citation: Am J Respir Crit Care Med. 2007 Nov 15;176(10):957-69
references.pmid: 17761616
references.citation: Value Health. 2013 Jan-Feb;16(1):3-13
references.pmid: 23337210
references.citation: J Cyst Fibros. 2009 Mar;8(2):91-6
references.pmid: 18952504
references.citation: Disabil Rehabil. 1998 Jun-Jul;20(6-7):262-71
references.pmid: 9637935
references.citation: Pediatr Pulmonol. 2002 Aug;34(2):91-100
references.pmid: 12112774
references.citation: Respir Care. 2004 Dec;49(12):1504-8
references.pmid: 15571641
references.citation: Patient Prefer Adherence. 2012;6:39-48
references.pmid: 22272068
references.citation: J Chemother. 2009 Apr;21(2):188-92
references.pmid: 19423472
references.citation: Paediatr Respir Rev. 2001 Sep;2(3):260-7
references.pmid: 12052328
references.citation: Pharmacoeconomics. 2011 Nov;29(11):977-88
references.pmid: 21854079
references.citation: Child Care Health Dev. 2007 Jul;33(4):491-5
references.pmid: 17584406
references.citation: Diabet Med. 2009 Apr;26(4):416-24
references.pmid: 19388973
references.citation: Expert Opin Pharmacother. 2008 Apr;9(5):751-66
references.pmid: 18345953